Relevance of implementing a logistic approach to innovation management in the development and registration of medicines for the treatment of coronavirus disease (COVID-19)

Authors

DOI:

https://doi.org/10.24959/sphhcj.20.189

Keywords:

COVID-19, logistics innovation and information system, innovation and information flows, innovation, medicine

Abstract

Aim. To analyze and summarize the existing scientific approaches and mechanisms for innovation management when developing and registering medicines for the treatment of coronavirus disease (COVID-19) based on the implementation of a logistic approach and the creation of the integrated logistics innovation and information system.

Materials and methods. Databases of the Internet, such as PubMed, the Food and Drug Administration, the European Medicines Agency were used. The retrospective, logical, and graphical methods of research, as well as the content analysis were applied.

Results. In order to overcome the current therapeutic crisis in the world, 2 strategies are used: repurposing of the existing drugs (favipiravir, tocilizumab, etc.) and development of candidates for drugs with a direct targeted mechanism of action against COVID-19 (remdesivir, vaccines, etc.). Traditional approaches to the innovative process of activity as a closed one, oriented to the internal environment of the innovation system become ineffective. For this purpose, it is promising to apply a logistic approach to innovation management in the development and registration of medicines for the treatment of coronavirus disease (COVID-19). In the conditions of open innovation processes, those organizations and countries that can quickly implement an innovative idea gain a competitive advantage. It is necessary to manage innovation processes so that when an innovative idea enters the first stage, the idea is transformed into the final product with the shortest possible time. Logistization of innovation activities involves continuous improvement and optimization of the existing processes, allows you to organize innovation processes as a through integrated flow, reduce the time and costs for the implementation of innovative projects, gain benefits by optimizing innovative information, material and other flows.

Conclusions. The result of the logistics of innovation in pharmacy will be: the creation of a complete cycle – from scientific research in scientific institutions, universities, pharmaceutical companies to the development of the production of innovative drugs; optimizing the use of resources associated with the implementation of innovative projects, as well as reducing the duration of the implementation of these projects; creation of a modern innovative infrastructure in the industry; wider attraction of investments in R&D from extra-budgetary sources; use of R&D results in training specialists.

Author Biographies

O. V. Posilkina, National University of Pharmacy

Doctor of Pharmacy (Dr. habil.), professor of the Department of Management, Economics and Quality Assurance in Pharmacy

O. V. Litvinova, National University of Pharmacy

Doctor of Pharmacy (Dr. habil.), associate professor of the Department of Management, Economics and Quality Assurance in Pharmacy

A. G. Lisna, National University of Pharmacy

Candidate of Pharmacy (Ph.D.), teaching assistant of the Department of Management, Economics and Quality Assurance in Pharmacy

References

World Health Organization. (2020). Novel Coronavirus (2019-nCoV): Strategic Preparedness and Response Plan. Geneva. Available at: https://www.who.int/docs/default-source/coronaviruse/covid19-strategy-update-2020-ru.pdf.

Kotvitska, A. A. et al. (Eds.). (2019). Modern pharmacy: history, realities and prospects of development: proceedings of the scientific and practical conference with the international participation dedicated to the 20th anniversary of the foundation of the Day of the Pharmaceutist of Ukraine (Vols 1-2; Vol. 2). Kharkiv, 498.

Schuhmacher, A., Gassmann, O., Hinder, M. (2016). Changing R&D models in research-based pharmaceutical companies. J Transl Med, 14, 105. doi: https://doi.org/10.1186/s12967-016-0838-4.

Sovet Evropy obsuzhdaet vozvrashchenie proizvodstva AFI v ES. (2020). Ezhenedelnik “Apteka”, 19 (1240). Available at: https://www.apteka.ua/article/546607.

Hryhorak, M. Yu., Savchenko, L. V. (Eds.). (2015). Innovative logistics: concepts, models, trend mechanisms. Kyiv: Lohos, 548 p.

Akulov, M. H., Pomircha, O. M. (2014). Naukovyi visnyk Khersonskoho derzhavnoho universytetu. Ser. : Ekonomichni nauky, 7 (2), 111-113.

Poliakova, D. (2020). Ezhenedelnik “Apteka”, 1234 (13). Available at: https://www.apteka.ua/article/541569.

WHO. (2020). R&D Blueprint. Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection. Geneva, Switzerland. Available at: https://apps.who.int/iris/handle/10665/330680.

Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (Released by the National Health Commission & National Administration of Traditional Chinese Medicine. (2020).Chinese Medical Journal, 133 (9), 1087-1095. doi: https://doi.org/10.1097/CM9.0000000000000819.

Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. (2020). Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and.

Zastosuvannia likiv pry COVID-19. (2020). Available at: http://covid19.dec.gov.ua/#rec188570508.

Sarah, C. J. J., Kebriaei, R., Dresser, L. D. (2020). Remdesivir: Review of Pharmacology, Pre-Clinical Data, and Emerging Clinical Experience for COVID-19. Pharmacotherapy. doi: https://doi.org/10.1002/phar.2429.

Nakaz Ministerstva okhorony zdorovia Ukrainy vid 02 kvitnia 2020 roku No. 762 (u redaktsii nakazu Ministerstva okhorony zdorovia Ukrainy vid 10 kvitnia 2020 roku No. 852) “Protokol nadannia medychnoi dopomohy dlia likuvannia koronavirusnoi khvoroby (COVID-19)”. (2020). moz.gov.ua. Available at: https://moz.gov.ua/uploads/3/19829-protokol.pdf.

Coomes, E. A., Haghbayan, H. (2020). Favipiravir, an Antiviral for COVID-19? The Journal of Antimicrobial Chemotherapy, 75 (7), 2013–2014. doi : https://doi.org/10.1093/jac/dkaa171.

Khiali, S., Elnaz, K., Taher, E.-M. (2020). A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome. Journal of Clinical Pharmacology. doi: https://doi.org/10.1002/jcph.1693.

Nakaz MOZ Ukrainy vid 14.05.2020 No. 1138 “Pro provedennia klinichnykh vyprobuvan likarskykh zasobiv, pryznachenykh dlia zdiisnennia zakhodiv, spriamovanykh na zapobihannia vynyknenniu ta poshyrenniu, lokalizatsiiu ta likvidatsiiu koronavirusnoi khvoroby (COVID-19)”. (2020). moz.gov.ua. Available at: https://moz.gov.ua/uploads/4/20662-dn_20200514_1138_dod.pdf.

Mahase, E. (2020). Covid-19: Demand for Dexamethasone Surges as RECOVERY Trial Publishes Preprint. BMJ, m2512. doi: https://doi.org/10.1136/bmj.m2512.

Grenfell, R., Drew, T. Here’s Why It’s Taking So Long to Develop a Vaccine for the New Coronavirus. ScienceAlert. Available at: https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away.

Bohazova, A. T. (2018). Dostizheniia nauki i obrazovaniia, 12 (34), 1-3.

Published

2020-09-09

Issue

Section

Social medicine and pharmacy: past, present and development prospects